Comac Medical Ltd. and its spin-offs – Comac Medical Phase I Unit, Laboratories, and International Research Network – have been monitoring the global COVID-19 pandemic since the beginning of this year and are constantly reviewing the risks based on the established company business continuity plan and actual situation. We want to assure our partners that we remain committed to business continuity, while at the same time protecting trial participants and employees.
We are keeping abreast of guidance from the World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), the European Commission (EC), as well as other global health organizations.
We recognize that the situation is evolving and, therefore, we would like to share with you the official FDA, EC and EMA guidance which we adhere to in relation to the conduct of clinical trials in the context of increased risk of COVID-19.
Stay safe!
